
#### Response to HIV

#### LOGISTICAL AND OTHER PERSPECTIVES









#### Margaret Brandeau

Department of Management Science and Engineering

Department of Medicine


Stanford University

### **Topics**

- HIV: A humanitarian crisis
- Planning for HIV response
- Barriers to program implementation
- Competing HIV priorities
- Health systems integration


#### HIV in sub-Saharan Africa

#### Global HIV/AIDS prevalence = 0.8%



# Antiretroviral therapy coverage

Actual and projected numbers of people receiving antiretroviral therapy in low- and middleincome countries by WHO region and in high-income countries across WHO regions, 2003–2015




#### HIV in South Africa

- 0.7% of world population; 17% of HIV cases
- 1 in 8 persons is infected (12% prevalence)
  - Blacks: 13% prevalence
  - Coloreds: 3% prevalence
  - Whites: 1% prevalence
- 1 in 6 adults aged 15-49 is infected (17% prevalence)
- 2.7 million people receiving antiretroviral therapy (ART)
- 900 new cases per day, 500 deaths per day
- This is a humanitarian crisis!

#### HIV prevalence in SA by age and sex

Figure 1: HIV prevalence by age and sex, South Africa, 2012



# Key issues in responding to HIV

- Getting infected individuals on ART is critical
  - Longer life, economic productivity, fewer orphans, ...
  - Reduced infectivity → prevents HIV spread
- HIV prevention programs are also critical
  - For every person newly enrolled in treatment, two more people become HIV infected!
- How to scale up HIV prevention and treatment?
  - Logistical and operational issues
  - Barriers to implementation

### **Topics**

- HIV: A humanitarian crisis
- Planning for HIV response
- Barriers to program implementation
- Competing HIV priorities
- Health systems integration

#### HIV Response

- "The right program in the right place at the right time"
- HIV treatment for all eligible individuals
  - Screening → linkage to care → retention in treatment → viral load suppression
- HIV prevention programs
  - Different risk groups (age, gender, risk behaviors)
  - Different geographic settings (urban, rural, ...)

- Policy, advocacy and stakeholder mobilization
- Community mobilization
- Service delivery design
- Supply and management of commodities
- Capacity-building and training
- Management and coordination
- Determining costs and obtaining financing

# Policy, advocacy, stakeholder mobilization

- Build and maintain political commitment
- Involve and coordinate a range of stakeholders
- Ensure involvement of persons living with HIV
- Work to influence health sector policies
- Promote a rights-based approach to HIV prevention and treatment
- Understand the regulatory environment for medicines and medical supplies

### Community mobilization

- Engage community members in HIV prevention and treatment efforts
- Provide information about HIV prevention and treatment efforts
- Address perceptions about the benefits (or lack of benefits) of proposed efforts

# Service delivery design

- Determine what services are to be offered, to which individuals and by which providers
  - Standardized protocols and quality standards, avoidance of stigma and discrimination
- Determine the setting (e.g., mobile intervention, communitybased, hospital-based)
- Plan the service delivery
  - Number of individuals potentially reached, infrastructure needs, space needs, human resource needs, training needs, need for medicines and medical supplies, plan for monitoring and evaluation

#### Supply, management of commodities

#### 1. Estimate needed supplies

 HIV test kits, specimen collection kits, HIV medications, refrigeration units, condoms, educational materials, equipment for training providers (e.g., videos), ...

#### 2. Procure supplies

- Purchased: determine sources and acceptable prices, product quality, expiration dates, and delivery timelines
- Donated: inform donors of how much is needed and quality standards, assess reliability of delivery times and quantities, beware of hidden costs (e.g., storage and distribution fees)

### Supply, management of commodities

#### 3. Distribute supplies

 Acquire needed facilities/equipment for storage and transport, manage the supply chain (e.g., inventory control, storage, transport), monitor and evaluate the supply chain

#### 4. Use supplies

 Adhere to program guidelines, obtain feedback about amount of items used and acceptability of supplies to patients and providers

# Capacity-building and training

- Build capacity in a coordinated way
  - Range of providers (public, private, NGO)
  - Range of geographic areas and population groups
  - Potential new settings for service delivery
- Develop human resources
  - Recruitment, training and retention of appropriate numbers and types of program personnel

#### Management and coordination

- Develop an appropriate management system
  - Advisory functions, day-to-day management, monitoring and evaluation
- Coordinate HIV prevention and treatment activities
  - National, regional, local levels
- Coordinate activities with other relevant services and stakeholders
  - Maternal and child health services, mental health services, other health services, ...


### Determining costs, obtaining financing

- Develop accurate cost estimates
  - Number of people potentially reached, startup and ongoing costs for facilities, staff and supplies
- Obtain financing
  - Variety of funding sources (local and central government, private sector, national and international donors, NGOs, local fundraising)

### **Topics**

- HIV: A humanitarian crisis
- Planning for HIV response
- Barriers to program implementation
- Competing HIV priorities
- Health systems integration

#### The HIV care cascade



achieve viral load

suppression.

### Challenges in HIV treatment scale up

- Community acceptability and protection of human rights
- Equity concerns
- Safe and acceptable first-line ART regimen
- Programmatic challenges
  - Scale up of HIV testing
  - Linkage into HIV care programs
  - ART delivery systems
  - Monitoring and reporting systems
  - Financing

# Challenges in HIV prevention

- VOICE trial (Vaginal and Oral Interventions to Control the Epidemic)
  - NIH-funded clinical trial
  - Vaginal gel; oral pre-exposure prophylaxis
  - 5029 women in Uganda, Zimbabwe, and South Africa
- Reported adherence: 90%
- Fraction of women with the drug in their blood: 25-30%
- Trial was halted prematurely due to high infection rate in intervention arm

#### Why did the VOICE trial fail?

- Difficulty in taking a pill every day
- Misaligned incentives
  - Large stipends for participating
  - Free contraception, HIV tests, gynecological exams
- Mistrust and lack of information
  - "HIV won't happen to me"
  - The drugs "cause liver cancer," "rot the uterus"
  - The investigators "are secretly spreading HIV"
- Cultural barriers

### **Topics**

- HIV: A humanitarian crisis
- Planning for HIV response
- Barriers to program implementation
- Competing HIV priorities
- Health systems integration

# Competing HIV priorities

#### **HIV TREATMENT**

- Testing
- Linkage to care
- Social support programs
- Retention in care
- Viral load monitoring
- Viral suppression

#### **HIV PREVENTION**

- Testing and counseling
- Condom promotion
- Voluntary male circumcision
- Prevention of mother-tochild transmission
- Programs targeted to other at-risk populations

#### How to evaluate interventions?

- Quantifiable outcomes
  - Costs
  - Health benefits
- Non-quantifiable outcomes
  - Equity, equality, fairness, justice
  - Social and political considerations (e.g., individual freedom, privacy, security, social norms)
  - Ethical and moral considerations
  - Robustness and implementability

### **Topics**

- HIV: A humanitarian crisis
- Planning for HIV response
- Barriers to program implementation
- Competing HIV priorities
- Health systems integration

### Competing health priorities

- HIV treatment and prevention
- Tuberculosis, malaria
- Other infectious diseases
  - Diarrheal diseases, respiratory diseases, typhoid, hepatitis, ...
- Non-communicable diseases
  - Diabetes, heart disease, hypertension, cancer, ...
- Maternal and child health
- Mental health

• ...

# Health systems integration

- How to integrate HIV care into new and existing health systems?
- How to integrate NGOs into new and existing health systems?



#### Investing in an HIV education program

Suppose an HIV education program reduces risky behavior by 80% and costs \$10,000.

Should we invest in it?

What if the reduction is 50%? 25%? 10%? 5%?

# Health policy: Quantifiable factors

- Monetary costs and savings
  - Cost of an intervention
  - Savings in health care costs
- Health outcomes
  - Reduction in number of inpatient days
  - Number of infections prevented
  - Number of years of life gained
  - Number of quality-adjusted life years (QALYs) gained
  - Number of disability-adjusted life years (DALYs) averted

# What is cost-effectiveness analysis?

- Cost-effectiveness analysis (CEA) is a formal method for comparing the costs of a medical intervention with its benefits to determine whether the intervention is worth doing
- Ultimate goal of CEA is to inform resource allocation decisions

#### Cost-effectiveness ratio

Cost effectiveness ratio =

(incremental costs of an intervention)

(incremental benefits of the intervention)

For example: the incremental CE ratio of screening compared to no screening is

 $\frac{(\text{Costs}_{\text{Screened}} - \text{Costs}_{\text{Unscreened}})}{(\text{Benefits}_{\text{Screened}} - \text{Benefits}_{\text{Unscreened}})}$ 

"Screened" refers to cohort of patients who were screened "Unscreened" refers to cohort of patients who were not screened

#### Costs and benefits: Societal perspective

- Measure all costs and benefits, regardless of source or beneficiary
- E.g., for costs: patient costs, health care provider costs, employer costs, costs of the criminal justice and welfare systems
- E.g., for benefits: health outcomes for patients, their contacts and offspring

#### Measurement of costs/savings

- Costs/savings = Changes in resource use associated with an intervention (i.e., incremental resources consumed)
- Must consider all costs/savings, regardless of source or beneficiary
- Must express all costs/savings in \$ of same year

# Categories of costs/savings

- Costs of health care services
- Costs of patient time
- Costs associated with care giving (paid or unpaid)
- Other costs associated with illness (e.g., childcare)
- Costs incurred by employers
- Costs associated with non-health impacts of intervention (e.g., welfare costs, criminal justice costs, environmental costs)

### Measurement of benefits

- Health benefits = improvement in health associated with an intervention
- Can measure in natural units for the intervention
  - E.g., reduction in hospital patient days, disease progression, years of sight saved, infections averted, life years gained, ...
- But ... to be able to compare with other interventions, must use a common measure
  - QALYs (quality-adjusted life years)
  - DALYs (disability-adjusted life years)


# Quality adjustment (QALYs)

- Time spent in each health state is weighted by a quality multiplier that is intended to reflect relative quality of life in that health state
- "Perfect health" has quality multiplier 1.0
- Death has quality multiplier 0
- For other health states, quality multipliers reflect diminution of health (e.g., pain/suffering, vision, hearing, speech, cognition, emotion, mobility, dexterity, ...)

# Disability adjustment (DALYs)

- Time spent in each health state is weighted by a disability multiplier (ranging from 0 to 1) that is intended to reflect losses in an individual's potential contribution to society
- Weights based on
  - Time lost due to premature death
  - Social value of time lived at different ages
  - Disability
  - Discounting (time preference)


# DALYs lost due to death at each age




# Spending a budget

Program	Cost	QALYs Gained	CE Ratio
Α	\$3.0 m	1000	\$3,000
В	\$3.2 m	500	\$6,400
С	\$2.0 m	100	\$10,000
D	\$1.8 m	100	\$18,000
Е	\$2.2 m	100	\$22,000


### Choosing from alternative interventions




### Efficient frontier in CEA



#### Incremental cost-effectiveness ratio



### Incremental CE ratio



# Interpreting the incremental CE ratio

- WHO guidelines
  - Very cost-effective interventions gain each additional QALY (or DALY) at a cost less than GDP per capita
  - Cost-effective interventions gain each additional QALY (or DALY) at a cost less than three times the GDP per capita

# GDP per capita for selected countries

Qatar	\$143,400	
Norway	\$66,900	
U.S.	\$54,600	
U.K.	\$39,500	
Russia	\$24,800	
China	\$12,900	
South Africa	\$12,700	
India	\$5,900	
Congo	\$700	